Lexology September 4, 2024
McGuireWoods Consulting LLC

Click here to listen to the audio.

A revolution in the use of psychedelic drugs to treat mental health issues experienced a setback in early August when the FDA declined to approve MMDA as a treatment for post-traumatic stress disorder.

Host Stephanie Kennan provides important context to the FDA’s decision, which...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Conferences / Podcast, FDA, Govt Agencies, Mental Health, Pharma, Pharma / Biotech, Provider, Trends
5 Ways AI Can Help Mental Health Clinicians Manage a Growing Caseload
Cerebral CEO Steps Down, Founds New Behavioral Health Triage Venture
The future of psychiatry: How AI and genetics are reshaping mental health care
To Improve Mental Health, Let's Address the 'Causes of the Causes,' Expert Says
Acadia Healthcare Leadership Focuses on 2026 Growth Strategy Despite 2024 Financial Challenge

Share This Article